Published in Cell Metab on October 01, 2006
Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab (2008) 2.17
PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab (2010) 1.77
Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab (2012) 1.64
PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta (2011) 1.60
PPARgamma in human and mouse physiology. Biochim Biophys Acta (2007) 1.58
Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPARγ activation to decrease diet-induced obesity. Cell Metab (2012) 1.54
Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res (2008) 1.48
Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes (2010) 1.42
Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes. Proc Natl Acad Sci U S A (2014) 1.21
Sequence-based prioritization of nonsynonymous single-nucleotide polymorphisms for the study of disease mutations. Am J Hum Genet (2007) 1.20
A functional peroxisome proliferator-activated receptor-gamma ligand-binding domain is not required for adipogenesis. J Biol Chem (2008) 1.16
Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension (2009) 1.06
Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res (2009) 1.03
Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem (2010) 1.00
Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Proc Natl Acad Sci U S A (2011) 1.00
The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells (2012) 1.00
Exome sequencing and genetic testing for MODY. PLoS One (2012) 1.00
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care (2013) 0.98
Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity. Mol Endocrinol (2009) 0.95
'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. PPAR Res (2007) 0.94
Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. Eur J Heart Fail (2009) 0.94
Suppression of PPARγ through MKRN1-mediated ubiquitination and degradation prevents adipocyte differentiation. Cell Death Differ (2013) 0.92
Association of genetic polymorphism of PPARγ-2, ACE, MTHFR, FABP-2 and FTO genes in risk prediction of type 2 diabetes mellitus. J Biomed Sci (2013) 0.92
Obesity and lipodystrophy--where do the circles intersect? Endocrinology (2008) 0.91
A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice. PLoS Med (2008) 0.91
PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues. PPAR Res (2010) 0.88
Hsp90 chaperones PPARγ and regulates differentiation and survival of 3T3-L1 adipocytes. Cell Death Differ (2013) 0.88
Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis. Open Rheumatol J (2012) 0.88
Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma. Curr Opin Nephrol Hypertens (2015) 0.87
Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy. Oncotarget (2012) 0.86
Prospective functional classification of all possible missense variants in PPARG. Nat Genet (2016) 0.85
Adipocytes in skin health and disease. Cold Spring Harb Perspect Med (2014) 0.85
Targeting adipose tissue via systemic gene therapy. Gene Ther (2014) 0.84
PPARγ2 polymorphism and human health. PPAR Res (2009) 0.82
Distribution and genotype frequency of the C1431T and pro12ala polymorphisms of the peroxisome proliferator activator receptor gamma gene in an Iranian population. Indian J Hum Genet (2013) 0.82
Genetics in endocrinology: genetic forms of severe insulin resistance: what endocrinologists should know. Eur J Endocrinol (2013) 0.80
Analysis of RXR/THR and RXR/PPARG2 heterodimerization by bioluminescence resonance energy transfer (BRET). PLoS One (2013) 0.80
A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system. Arterioscler Thromb Vasc Biol (2013) 0.78
Neuroanatomical characterisation of the expression of the lipodystrophy and motor-neuropathy gene Bscl2 in adult mouse brain. PLoS One (2012) 0.78
Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? PPAR Res (2015) 0.77
Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. PLoS One (2013) 0.77
Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome. World J Diabetes (2015) 0.77
Founder effect in the Horn of Africa for an insulin receptor mutation that may impair receptor recycling. Diabetologia (2011) 0.77
PKA regulatory subunit R2B is required for murine and human adipocyte differentiation. Endocr Connect (2013) 0.76
New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand. J Med Genet (2007) 0.76
Original Research: Polyphenols extracted from grape powder induce lipogenesis and glucose uptake during differentiation of murine preadipocytes. Exp Biol Med (Maywood) (2016) 0.75
Single-Nucleotide Polymorphism of PPARγ, a Protein at the Crossroads of Physiological and Pathological Processes. Int J Mol Sci (2017) 0.75
Molecular spectrum of TSHβ subunit gene defects in central hypothyroidism in the UK and Ireland. Clin Endocrinol (Oxf) (2016) 0.75
Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases? Int J Mol Sci (2016) 0.75
Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver. Mol Ther Methods Clin Dev (2017) 0.75
The Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARG) in Adipogenesis: Applying Knowledge from the Fish Aquaculture Industry to Biomedical Research. Front Endocrinol (Lausanne) (2017) 0.75
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet (2000) 15.19
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 13.34
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev (1994) 10.44
Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (1995) 10.42
PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell (1999) 10.08
Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev (1999) 9.94
Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev (2003) 9.93
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell (1999) 9.74
A vector for expressing GAL4(1-147) fusions in mammalian cells. Nucleic Acids Res (1989) 8.06
The many faces of PPARgamma. Cell (2005) 6.24
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature (2000) 5.86
Activation of PPARgamma coactivator-1 through transcription factor docking. Science (1999) 4.33
Steroid hormone receptors compete for factors that mediate their enhancer function. Cell (1989) 3.50
RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet (1999) 3.43
Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature (2002) 3.42
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res (1996) 3.36
Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev (2005) 3.30
Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes (2003) 3.28
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem (1997) 3.19
Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell (2000) 3.01
Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor. EMBO J (1994) 2.62
Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev (1997) 2.41
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes (2003) 2.28
Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med (1995) 2.20
Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol (2001) 2.12
Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem (1997) 2.10
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell (2001) 2.02
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol (2003) 1.96
Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem (1997) 1.88
A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem (2000) 1.87
The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev (1999) 1.84
PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes (2002) 1.77
PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun (1999) 1.76
Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem (2004) 1.75
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology (2003) 1.69
A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab (2002) 1.61
Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem (1998) 1.58
Identification of a fat cell enhancer: analysis of requirements for adipose tissue-specific gene expression. J Cell Biochem (1992) 1.54
A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nat Struct Biol (2003) 1.50
A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem (1998) 1.48
Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr (1996) 1.42
Differential DNA binding by monomeric, homodimeric, and potentially heteromeric forms of the thyroid hormone receptor. Mol Cell Biol (1991) 1.40
Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J Biol Chem (2006) 1.39
Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci U S A (2002) 1.36
The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents. J Biol Chem (2002) 1.36
Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet (2002) 1.36
Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity (2004) 1.32
Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome. Mol Endocrinol (1994) 1.17
Thyroid hormone action in the absence of thyroid hormone receptor DNA-binding in vivo. J Clin Invest (2003) 1.16
A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing. J Biol Chem (2005) 1.12
Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization. Cell Death Differ (2003) 1.09
Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem (1996) 1.09
Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor gamma. J Biol Chem (2002) 1.07
An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor gamma (PPARgamma) binding and activation on some PPAR response elements. J Biol Chem (2004) 1.06
Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera. J Biol Chem (1998) 1.03
Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol (2002) 1.01
A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol Endocrinol (1999) 1.00
PPAR gamma as a metabolic regulator: insights from genomics and pharmacology. Expert Rev Mol Med (2005) 0.99
A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J Clin Endocrinol Metab (2004) 0.98
A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia (2003) 0.96
Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. Endocrinology (2005) 0.95
Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene. J Biol Chem (2000) 0.87
Ligand-dependent cross-talk between steroid and thyroid hormone receptors. Evidence for common transcriptional coactivator(s). J Biol Chem (1996) 0.87
Cytoplasmic-nuclear trafficking of steroid hormone receptors. Trends Endocrinol Metab (1993) 0.84
Transcriptional repression by nuclear receptors: mechanisms and role in disease. Biochem Soc Trans (2000) 0.83
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet (2008) 16.92
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science (2007) 9.86
The GPR54 gene as a regulator of puberty. N Engl J Med (2003) 9.54
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med (2004) 8.36
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet (2012) 6.97
Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med (2003) 6.87
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
LDL-cholesterol concentrations: a genome-wide association study. Lancet (2008) 6.44
Moderate to vigorous physical activity and sedentary time and cardiometabolic risk factors in children and adolescents. JAMA (2012) 6.43
The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet (2012) 6.15
Combined impact of health behaviours and mortality in men and women: the EPIC-Norfolk prospective population study. PLoS Med (2008) 6.14
The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet (2011) 5.95
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest (2002) 5.83
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Genetics of obesity in humans. Endocr Rev (2006) 5.42
Large, rare chromosomal deletions associated with severe early-onset obesity. Nature (2009) 5.20
Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genet (2010) 4.95
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Meta-analysis of genome-wide scans for human adult stature identifies novel Loci and associations with measures of skeletal frame size. PLoS Genet (2009) 4.24
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes (2008) 4.11
Are imprecise methods obscuring a relation between fat and breast cancer? Lancet (2003) 4.10
Genome-wide association study identifies five loci associated with lung function. Nat Genet (2009) 4.10
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest (2010) 3.91
The UK10K project identifies rare variants in health and disease. Nature (2015) 3.89
PPAR gamma and human metabolic disease. J Clin Invest (2006) 3.83
Use of accelerometers in a large field-based study of children: protocols, design issues, and effects on precision. J Phys Act Health (2008) 3.81
Obesity associated genetic variation in FTO is associated with diminished satiety. J Clin Endocrinol Metab (2008) 3.80
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation (2007) 3.71
The hormonal control of food intake. Cell (2007) 3.61
Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet (2007) 3.58
A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science (2004) 3.54
Significant linkage of BMI to chromosome 10p in the U.K. population and evaluation of GAD2 as a positional candidate. Diabetes (2006) 3.51
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Leptin regulates striatal regions and human eating behavior. Science (2007) 3.31
Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol (2006) 3.31
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation (2007) 3.20
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Modernising medical careers, medical training application service, and the postgraduate medical education and training board: time for the emperors to don their clothes. Lancet (2007) 3.12
Genetic variation in LIN28B is associated with the timing of puberty. Nat Genet (2009) 3.09
Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology (2014) 3.06
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest (2007) 2.97
Why most conservation monitoring is, but need not be, a waste of time. J Environ Manage (2005) 2.92
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations. N Engl J Med (2015) 2.87